Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) will host its second quarter 2024 earnings conference call on Wednesday, July 31, 2024, at 8:30 a.m. ET. The Warsaw, Indiana-based medical device manufacturer will discuss its financial results for the period ending June 30, 2024, before the market opens, according to the company’s official investor relations disclosure.
Accessing the ZBH Earnings Webcast
Investors and interested parties can access the live audio webcast through the Zimmer Biomet Investor Relations website. The company typically provides a replay of the call on the same platform shortly after the live event concludes. Those planning to participate in the question-and-answer session should check the company’s portal for specific registration requirements or dial-in instructions, as these protocols often change ahead of quarterly releases.
Understanding the Financial Context
Zimmer Biomet specializes in musculoskeletal healthcare, providing products for knee and hip reconstruction, sports medicine, and craniomaxillofacial surgery. Analysts typically focus on the company’s revenue growth in its "Large Joints" segment and the adoption rate of its ROSA robotics platform.
In the first quarter of 2024, the company reported net sales of $1.94 billion, representing a 4.0% increase on a reported basis compared to the same period in 2023. Investors will be looking to see if this growth trajectory continued through the second quarter, particularly as the medical device industry faces ongoing shifts in elective procedure volumes and hospital capital expenditure budgets.
Market Expectations and Key Metrics
Wall Street analysts track several specific metrics when evaluating Zimmer Biomet’s performance:
- Organic Revenue Growth: This measures core business performance by excluding the impact of foreign currency fluctuations and acquisitions.
- Adjusted Earnings Per Share (EPS): A primary indicator of operational profitability.
- Operating Margin: Insights into how effectively the firm is managing costs amidst inflationary pressures in logistics and raw materials.
The company’s performance in the second quarter serves as a significant bellwether for the broader orthopedic sector. Because elective surgery volumes are highly sensitive to patient insurance coverage and hospital staffing levels, the commentary from the executive leadership team regarding market trends for the remainder of the year will likely carry as much weight as the raw financial data.
Company Profile
Zimmer Biomet operates in over 25 countries and sells products in more than 100 nations. Headquartered in Warsaw, Indiana, the firm was formed through the 2015 merger of Zimmer Holdings and Biomet. As a constituent of the S&P 500, its financial disclosures are subject to rigorous regulatory oversight by the U.S. Securities and Exchange Commission (SEC).
For the most recent financial statements and reconciliation of non-GAAP measures, investors should refer to the official SEC filings published by the company.